Gilteritinib for Patients with Newly Diagnosed AML

Data from the worldwide MORPHO study, presented by Professor Mark Levis, aims to answer the question if patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML) who are undergoing allogeneic stem cell transplantation should be treated with gilteritinib as maintenance therapy. Even though not all patients seem to benefit from this treatment, Mark Levis highlights that in around 50% of the patients from the study, who were MRD-positive, gilteritinib appears to have had a significantly positive effect.